By Adriano Marchese
Zentalis Pharmaceuticals shares were down in premarket trading after the company said partial clinical holds were placed on three of its cancer treatment studies.
Ahead of the morning bell, shares were trading nearly 27% lower at $6.15.
The clinical-stage biopharmaceutical said the U.S. Food and Drug administration has placed a partial clinical hold on studies for its drug, Azenosertib.
The company said it is working with the regulator to resolve the partial clinical hold as quickly as possible.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
06-18-24 0759ET